A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics

about

A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics

Item

http://www.wikidata.org/entity/Q36512012

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A Quantitative Assessment of F ...... ption of Companion Diagnostics

@ast

A Quantitative Assessment of F ...... ption of Companion Diagnostics

@en

type

Item

label

A Quantitative Assessment of F ...... ption of Companion Diagnostics

@ast

A Quantitative Assessment of F ...... ption of Companion Diagnostics

@en

prefLabel

A Quantitative Assessment of F ...... ption of Companion Diagnostics

@ast

A Quantitative Assessment of F ...... ption of Companion Diagnostics

@en

P1476

A Quantitative Assessment of F ...... ption of Companion Diagnostics

@en

P2093

A Schuh

http://www.w3.org/2001/XMLSchema#string

David A Brindley

http://www.w3.org/2001/XMLSchema#string

David L DiGiusto

http://www.w3.org/2001/XMLSchema#string

Dee Luo

http://www.w3.org/2001/XMLSchema#string

Katie E Manescu

http://www.w3.org/2001/XMLSchema#string

Kim Bure

http://www.w3.org/2001/XMLSchema#string

Mike Kope

http://www.w3.org/2001/XMLSchema#string

Nick A Meadows

http://www.w3.org/2001/XMLSchema#string

Rob Horne

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Quantifying factors for the success of stratified medicine.

Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study

Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement

Health technology assessment and private payers' coverage of personalized medicine.

Points to consider in assessing and appraising predictive genetic tests.

Key factors in the rising cost of new drug discovery and development.

P304

357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FGENE.2015.00357

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Benjamin Davies

James A Smith

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26858745

http://www.w3.org/2001/XMLSchema#string

P932

4730156

http://www.w3.org/2001/XMLSchema#string